This CME-accredited activity is designed to enhance the care of patients with diffuse large B-cell lymphoma (DLBCL) by providing healthcare professionals with the latest clinical updates. The course highlights a multimodal treatment approach and integrates recent advances in patient-centered management for physicians, nurse practitioners, physician assistants, pharmacists, nurses, and other oncology care providers.

Course Accreditations

Course Summary

Target Audience

Medical oncologists
Oncology residents/fellows
Oncology NPs/PAs
Oncology pharmacists

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

Review management of early-stage DLBCL and the role of radiation therapy
Understand how cell of origin influences treatment decisions in DLBCL
Identify when to consider CAR-T and/or BiTE therapy for relapsed or refractory DLBCL
Recognize and manage complications associated with CAR-T and bispecific antibody therapies